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Background: Patients with advanced endocrine cancers, such as adrenocortical carcinoma and medullary thyroid
carcinoma, have few well-validated therapeutic options. Pre-clinical studies have suggested potential activity of
imatinib in these tumors. We therefore sought to establish a safe, novel treatment regimen combining imatinib with
cytotoxic chemotherapy for future study in endocrine cancers.
Methods: A standard 3 + 3 dose-escalation design was used with a 21-day cycle, including imatinib on days 1–21,
dacarbazine on days 1–3, and capecitabine on days 1–14.
Results: Twenty patients were treated. The most frequent toxicities were edema and fatigue, with dose-limiting
fatigue and dyspnea. The recommended phase II regimen is dacarbazine 250 mg/m2 daily on day 1–3, capecitabine
500 mg/m2 twice daily on days 1–14, and imatinib 300 mg daily on days 1–21 of a 21-day cycle. Interestingly,
responses were seen in patients with adrenocortical carcinoma, with 1 of 6 patients experiencing a partial response
and a second experiencing a minor response, with progression-free survival of 8.8 and 6.4 months, respectively.
Conclusions: The regimen of imatinib, dacarbazine, and capecitabine is well-tolerated. It may have some activity in
adrenocortical carcinoma, and further study of this combination or its components may be beneficial for this
disease with limited treatment options.
Trial registration: ClinicalTrials.gov identifier NCT00354523, registered July 18, 2006.Background
Endocrine cancers are a heterogeneous group of malig-
nancies. Adrenocortical carcinoma (ACC) and medullary
thyroid carcinoma (MTC) are challenging cancers to
treat if metastatic or unresectable, and few chemother-
apy regimens have proven effective for advanced disease.
Medullary thyroid carcinoma (MTC) is a rare tumor
arising from the parafollicular C cells of the thyroid
gland [1]. Approximately 75% of these tumors are spor-
adic and 25% are hereditary, associated with the multiple
endocrine neoplasia type 2 syndrome (MEN2) [2]. Mul-
tiple endocrine neoplasia type 2 is an autosomal domin-
ant syndrome caused by germline activating mutations
of the RET proto-oncogene which encodes for RET, a re-
ceptor tyrosine kinase that modulates C cell proliferation
and apoptosis [3-5]. Patients with sporadic MTC do not
carry germline RET mutations, but 40% of their tumors* Correspondence: jyao@mdanderson.org
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unless otherwise stated.carry a somatic RET mutation, most commonly involv-
ing exon 16, conferring a more aggressive phenotype
[6-9]. In vitro and in vivo studies of the most common
germline and somatic RET mutations have established
their role in oncogenesis [10-13]. In vitro studies using a
MTC cell line with a RET codon 634 mutation demon-
strated growth inhibition with imatinib, offering some
hope that the drug may have efficacy in this tumor [14].
Systemic cytotoxic chemotherapy for advanced MTC has
shown limited tumor response efficacy. Small trials study-
ing dacarbazine, 5-fluorouracil, and doxorubicin [15-20],
used alone or in combination, have demonstrated partial
biochemical and tumor responses in 10-20% of patients.
More recently, inhibitors of the RET kinase, such as van-
detanib [21] and cabozantinib [22], have shown evidence
of significant progression- free survival benefit, and hence
are FDA-approved for the treatment of patients with ad-
vanced MTC.
Adrenocortical carcinoma (ACC) is another rare ma-
lignancy of neuroectodermal origin with limited thera-
peutic options. It has an annual incidence of 1–2 casesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Dose levels
Level Imatinib Dacarbazine Capecitabine Patients (N) Dose reductions (N) DLTs1 (N and type)
−1 300 mg 250 mg/m2 500 mg/m2 BID 6 0 1 (fatigue)
1 400 mg 250 mg/m2 500 mg/m2 BID 6 2 9 (Dyspnea, Fatigue, Diarrhea, Dehydration, Nausea,
Ocular Surface Disease, Insomnia)
2 400 mg 330 mg/m2 750 mg/m2 BID 6 1 2 (Hypokalemia, platelets)
3 400 mg 330 mg/m2 1000 mg/m2 BID 0 0
4 600 mg 330 mg/m2 1000 mg/m2 BID 0 0
5 800 mg 330 mg/m2 1000 mg/m2 BID 0 0
Dose levels specified for protocol therapy. 1: DLTs – dose-limiting toxicities.




















Characteristics of patients enrolled on the study. Total n = 20. 1MTC – medullary
thyroid carcinoma; 2ACC – adrenocortical carcinoma; 3NET – neuroendocrine
tumor; 4Transitional cell carcinoma.
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vival that decreases dramatically as a function of clinical
stage, ranging from over 10 years for stage I disease to
less than 6 months with advanced stage [24]. Most cases
are sporadic, but associations have been demonstrated
with Li Fraumeni syndrome, Beckwith-Wiedemann syn-
drome, and MEN 1 [25,26]. While mitotane has been
the mainstay of therapy since it was demonstrated to re-
duce serum and urine steroid concentrations in over
70% of patients in 1966 [27], high-quality clinical evi-
dence for a survival benefit with any therapy was absent
until a recent trial demonstrated the utility of etoposide,
doxorubicin, cisplatin, and mitotane (EDP-mitotane) [28].
Molecularly targeted therapies have been of interest
[29-31], but none have yet proven successful. Of particular
interest was a study demonstrating that adrenocortical
carcinomas express cKit and/or the PDGF receptor at
some frequency, but are unresponsive to single-agent ima-
tinib [32].
Therefore, MTC and ACC require more effective
therapy. As most MTCs have upregulated RET activity
and pre-clinical studies using imatinib inhibit MTC
cell proliferation and induce apoptosis, this drug has
been appealing for treating this disease. ACC could
also theoretically respond to imatinib, perhaps when
combined with additional chemotherapy to allow for
cytotoxicity. We therefore undertook a phase I dose-
escalation trial of the combination of imatinib,
dacarbazine, and capecitabine in advanced endocrine




Men and women of all ethnic groups were eligible if
they were > 16 years old with an ECOG performance
status of 0–2 and any proven solid tumor for which no
curative or standard treatment was available, regardless
of prior therapy. Patients needed laboratory evidence
of adequate hepatic, renal, and bone marrow function,
as well as a negative pregnancy test (if applicable) andan agreement to use barrier contraception throughout
therapy.
Exclusion criteria
Patients were ineligible if they had received chemotherapy
or surgery within the last 3 weeks, or radiation within the
last 4 weeks. Patients could not have received prior treat-
ment with investigational agents within 28 days of study
entry. Severe concurrent illness or ongoing pregnancy or
lactation resulted in exclusion, as well. Patients with any
other malignancy, except non-melanoma skin cancer or an
MEN2-associated cancer, within the prior 5 years were also
ineligible. Finally, patients could not be receiving warfarin
during the study, though heparin products were allowed.
Table 3 Adverse events
Toxicity G1 G2 G3 G4 Total
Allergic rhinitis 2 1 0 0 3
Alopecia 2 0 0 0 2
ALT1 1 0 1 0 2
Anorexia 2 4 0 0 6
AST2 1 0 0 0 1
Bilirubin 1 0 0 0 1
Cardiac ischemia 0 0 1 0 1
Chest tightness 1 0 0 0 1
Constipation 4 4 0 0 8
Dehydration 0 0 1 0 1
Diarrhea 5 2 1 0 8
Distension 0 0 1 0 1
Dizziness 2 0 0 0 2
Dry mouth 1 0 0 0 1
Dry skin 1 0 0 0 1
Dysphagia 1 0 0 0 1
Dyspnea 2 2 6 0 10
Edema 12 1 0 0 13
Fatigue 5 3 5 0 13
Fever (no neutropenia) 1 0 0 0 1
Flushing 1 0 0 0 1
Hand-foot syndrome 1 0 0 0 1
Hemoglobin 1 2 0 0 3
Hypocalcemia 1 0 0 0 1
Hypokalemia 2 0 2 0 4
Hypomagnesemia 1 0 0 0 1
Insomnia 2 5 1 0 8
Mood alteration 0 1 0 0 1
Mucositis 4 0 0 0 4
Nausea 4 6 1 0 11
Neuropathy (sensory) 3 2 0 0 5
Neutrophils 0 2 1 0 3
Ocular surface disease 1 1 1 0 3
Ocular/visual 2 0 0 0 2
Pain 12 6 1 0 19
Palpitations 1 0 0 0 1
Platelets 1 0 0 0 1
Pleural effusion 1 0 0 0 1
Pruritis 1 0 0 0 1
Rash 6 0 0 0 6
Rigors/chills 2 0 0 0 2
Sinus tachycardia 1 0 0 0 1
Somnolence 3 0 0 0 3
Sweating 1 0 0 0 1
Table 3 Adverse events (Continued)
Taste alteration 5 4 0 0 9
Upper respiratory infection 1 0 0 0 1
Voice change 2 0 0 0 2
Vomiting 2 2 0 0 4
Watery eye 1 0 0 0 1
Adverse events reported according to the Cancer Therapy Evaluation Program
Common Toxicity Criteria, version 3.0. 1: ALT – alanine aminotransferase
elevation; 2: AST – aspartate aminotransferase elevation.
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All patients provided written informed consent meeting
M.D. Anderson Cancer Center Institutional Review Board
(IRB) and NCI standards.
The study was designed as a single-arm, open-label
dose-escalation study of imatinib, dacarbazine, and cape-
citabine. Imatinib was given orally on days 1–21, dacarba-
zine was given intravenously over 1 hour on Days 1–3, and
capecitabine was given orally twice daily on days 1–14. A
cycle of treatment was defined as 21 days with the next
cycle starting on Day 22. A standard 3 + 3 dose-escalation
scheme was utilized (Table 1).
The objective of the trial was to determine the
maximum tolerated dose (MTD) of the combination
of imatinib, dacarbazine, and capecitabine. Toxicities
were graded according to the Cancer Therapy Evalu-
ation Program Common Toxicity Criteria, version 3.0.
MTD was defined as the dose level below that produ-
cing dose-limiting toxicity (DLT; i.e. any Grade 4
hematologic toxicity and /or non-hematologic tox-
icity ≥Grade 3 except alopecia within the first 28 days)
in ≥ 33% of patients.
Baseline cross-sectional imaging by computed tomog-
raphy or magnetic resonance imaging was performed
within 28 prior to study enrollment, and response to
treatment was measured using the modified RECIST cri-
teria with radiological evaluation every 9 weeks.
Treatment continued until occurrence of disease pro-
gression, unacceptable toxicity, or the patient elected to
discontinue study participation.
The study was conducted in concordance with the
Declaration of Helsinki and approved by the MD
Anderson Cancer Center Institutional Review Board as
protocol 2004–0475.
Statistical considerations
Median progression-free survival (PFS) and overall sur-
vival (OS) were calculated by the Kaplan-Meier method.
Follow-up was calculated from date of study enrollment
until date of last contact. All statistical analyses were
performed using SPSS version 21.0.
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Patient demographics
From January 2005 through September 2006, 21 pa-
tients were screened and 20 patients were enrolled.
Their median age was 52 years (range 33–77 years)
(Table 2). Two patients did not complete the first cycle
of protocol therapy due to symptomatic or progressive
disease, and were excluded from analysis for DLT. The
patient population was enriched for patients with MTC
and ACC, but also included patient with pancreatic
neuroendocrine tumors, melanoma, and transitional
cell carcinoma. All patients were metastatic at time of
therapy initiation.
Dose escalation and maximum tolerated dose
An initial cohort of three patients was enrolled at dose level
1 (dacarbazine 250 mg/m2, capecitabine 1000 mg/m2 twice
daily, and imatinib 400 mg) without observing a DLT. The
next cohort of three patients was treated at dose level 2,
with one patient experiencing grade 3 hypokalemia. An
additional three patients were enrolled at this dose level,
with one experiencing grade 3 thrombocytopenia. There-
fore, three additional patients were enrolled at dose level 1,
with all patients experiencing a grade 3 toxicity, including 2Table 4 Patient outcomes








1 NET1 1 1 0 0
2 NET 1 0 0 0
3 MTC2 0 1 1 1
4 MTC 0 1 1 1
5 MTC 0 1 1 1
6 MTC 0 1 1 1
7 MTC 1 1 1 1
8 MTC 1 1 1 1
9 NET 1 1 0 1
10 ACC3 1 1 1 0
11 MTC 0 0 1 1
12 ACC 1 1 1 1
13 TCC4 1 1 1 0
14 ACC 1 1 1 0
15 MTC 0 0 1 0
16 ACC 1 1 1 0
17 ACC 1 0 1 0
18 Melanoma 1 1 1 1
19 ACC 1 1 1 0
20 ACC 1 1 0 0
Patient-specific characteristics and outcomes. 1NET – neuroendocrine tumor; 2MTC
4TCC – Transitional cell carcinoma. PD – progressive disease; SD – stable disease; M
XRT – radiation therapy.; Chemo lines – number of prior chemotherapies.patients with dyspnea and 2 with fatigue. When the next
cohort of three patients was enrolled in dose level −1, a
single patient experienced grade 3 fatigue. The final cohort
of three patients enrolled in dose level −1 and experienced
no DLT.
Safety
The most common toxicities for all cycles were fatigue
and edema, each occurring in 65% of patients (Table 3).
Edema was mostly grade 1, but 25% of patients described
grade 3 fatigue during treatment. The most common
grade 3 adverse event was dyspnea, with 30% of patients
describing that symptom. Most treatment-related adverse
effects were transient, and only one patient required dose
reduction.
Tumor responses
Overall, 18 of 20 patients reached first restaging. The
remaining two had expired from progressive disease. Of
those 18 patients, 12 had progressive disease, 6 had
stable disease, 1 had a minor response, and 1 had a con-
firmed partial response as best response to protocol
therapy. Intriguingly, both of the responses were seen in








1 2.1 13.5 PD
0 0.8 2.3 PD
4 14.2 93.3 SD
4 2.3 93.3 SD
2 7.4 66.7 SD
3 0.5 4.1 PD
1 2.3 20.3 PD
3 2.2 7.1 PD
3 0.5 0.5 Death
1 6.4 17.5 MR
0 7.7 88.6 PD
5 2.4 2.4 Death
6 2.6 9.1 PD
2 8.8 39.5 PR
0 6.3 82.0 SD
2 1.6 80.7 PD
0 1.7 79.5 PD
1 2.1 7.8 PD
2 2.1 13.4 PD
1 2.0 18.6 PD
– medullary thyroid carcinoma; 3ACC – adrenocortical carcinoma;
R – minor response; PR – partial response.
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5 patients with ACC experienced progressive disease. No
responses were seen in those patients with MTC, but 4
of 5 patients experienced stable disease (Table 4). How-
ever, all 4 patients entered the study with stable disease.
With a median follow-up of 82 months, the median PFS
was 2.3 months (95% CI 2–2.7), with median OS of
18.6 months (95% CI 8.8-28.4). Given the heterogeneity
of the patient population, patient-level survival informa-
tion is given in Table 4.Discussion
In this phase I study, we have evaluated the safety of the
combination of dacarbazine, capecitabine, and imatinib in
metastatic endocrine cancers. The recommended dose
regimen for a phase II trial is dacarbazine 250 mg/m2 daily
on day 1–3, capecitabine 500 mg/m2 twice daily on days
1–14, and imatinib 300 mg daily on days 1–21 of a 21-day
cycle. Dose-limiting toxicities most frequently included fa-
tigue, dyspnea, and minor electrolyte and blood count ab-
normalities. The combination was otherwise tolerated well.
We also revealed evidence of activity of this regimen
in ACC, even in the context of pretreated, refractory dis-
ease, a situation for which there are very limited effective
therapies. Impact on overall survival is challenging to as-
sess in the setting of a heterogeneous and uncontrolled
patient population with respect to previous treatments,
however, and overall survival was no better among the
two responders than among the five non-responders.
Since this trial was initiated, multiple studies have inves-
tigated the in vitro and in vivo activity of imatinib-based
regimens in MTC. Early studies of the in vitro effects dem-
onstrated RET inhibition and death of oncogene-addicted
MTC cells [14,33], but these studies demonstrated suc-
cessful RET inhibition only at serum concentrations that
could not be achieved with tolerable doses of imatinib, and
subsequent clinical trials of imatinib monotherapy revealed
no responses in MTC [32,34]. In one of these trials of ima-
tinib monotherapy, patients with ACC were included as
well, without evidence of clinical response [32]. Additional
investigation of this agent in ACC, alone or in combin-
ation with cytotoxic chemotherapy has otherwise been
lacking, making our combination entirely novel.Conclusion
We present here the results of phase I trial of a combin-
ation of targeted therapy using imatinib with cytotoxic
chemotherapy using capecitabine and dacarbazine in pa-
tients with advanced endocrine malignancies. Responses
were rare, but occurred exclusively in patients with ACC,
a cancer with limited effective therapies. These data
should prompt consideration of a phase II trial of such a
combination in this disease, given the paucity of otheroptions. Alternatively, our hope is that these results will
promote a deeper understanding of the disease biology in
those patients who responded, allowing for the insightful
and rational development of future targeted therapies.
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